Article

Use of immunohistochemical markers can refine prognosis in triple negative breast cancer

Program in Cancer Genetics, McGill University, Montréal, Québec, Canada.
BMC Cancer (Impact Factor: 3.32). 02/2007; 7(1):134. DOI: 10.1186/1471-2407-7-134
Source: PubMed

ABSTRACT Basal-like breast cancer has been extensively characterized on the basis of gene expression profiles, but it is becoming increasingly common for these tumors to be defined on the basis of immunohistochemical (IHC) staining patterns, particularly in retrospective studies where material for expression profiling may not be available. The IHC pattern that best defines basal-like tumors is under investigation and various combinations of ER, PR, HER2-, CK5/6+ and EGFR+ have been tested.
Using datasets from two different hospitals we describe how using different combinations of immunohistochemical patterns has different effects on estimating prognosis at different time intervals after diagnosis. As our baseline, we used two IHC patterns ER-/PR-/HER2-("triple negative phenotype", TNP) and ER-/HER2-/CK5/6+ and/or EGFR+ ("core basal phenotype", CBP).
There was no overall difference in survival between the two hospital-based series, but there was a difference between the TNP and non-TNP groups which was most marked at 3 years (76.8% vs 93.5%, p < .0001). This difference reduced with time, suggesting that long term survivors (beyond 10 years) in the TNP group may have comparable survival to non-TNP cases. A similar difference was seen if CBP was used instead of TNP. However when CK5/6 and/or EGFR expressing tumors were analyzed without consideration of ER/PR status, the reduction in survival increased with time, becoming more pronounced at 10 years than at 3 years.
Our findings suggests that CK5/6 and/or EGFR expressing tumor types have a persistently poorer prognosis over the longer term, an observation that may have important therapeutic implications as drugs that target the EGFR are currently being evaluated in breast cancer.

Download full-text

Full-text

Available from: Jean-Sébastien Brunet, Aug 12, 2015
0 Followers
 · 
271 Views
  • Source
    • "Indeed, we demonstrated that the overexpression of EGFR is capable of transforming mammary epithelial cells, and that transforming growth factor β (TGF-β)–mediated epithelial-mesenchymal transition (EMT) in concert with EGFR facilitates primary mammary tumor cell invasion and dissemination [1] [2]. Along these lines, primary breast tumors expressing elevated levels of EGFR display decreased clinical prognosis [3]. These and other findings point to the targeting of EGFR as an effective means by which to combat breast cancer (BC) metastasis. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Numerous studies by our lab and others demonstrate that epidermal growth factor receptor (EGFR) plays critical roles in primary breast cancer (BC) initiation, growth and dissemination. However, clinical trials targeting EGFR function in BC have lead to disappointing results. In the current study we sought to identify the mechanisms responsible for this disparity by investigating the function of EGFR across the continuum of the metastatic cascade. We previously established that overexpression of EGFR is sufficient for formation of in situ primary tumors by otherwise nontransformed murine mammary gland cells. Induction of epithelial-mesenchymal transition (EMT) is sufficient to drive the metastasis of these EGFR-transformed tumors. Examining growth factor receptor expression across this and other models revealed a potent downregulation of EGFR through metastatic progression. Consistent with diminution of EGFR following EMT and metastasis EGF stimulation changes from a proliferative to an apoptotic response in in situ versus metastatic tumor cells, respectively. Furthermore, overexpression of EGFR in metastatic MDA-MB-231 BC cells promoted their antitumorigenic response to EGF in three dimensional (3D) metastatic outgrowth assays. In line with the paradoxical function of EGFR through EMT and metastasis we demonstrate that the EGFR inhibitory molecule, Mitogen Induced Gene-6 (Mig6), is tumor suppressive in in situ tumor cells. However, Mig6 expression is absolutely required for prevention of apoptosis and ultimate metastasis of MDA-MB-231 cells. Further understanding of the paradoxical function of EGFR between primary and metastatic tumors will be essential for application of its targeted molecular therapies in BC.
    Neoplasia (New York, N.Y.) 01/2015; 29(1). DOI:10.1016/j.neo.2014.11.009 · 5.40 Impact Factor
  • Source
    • "Our results about the timing of recurrence are comparable to the data of previous investigators [54], the relapse events in our study had occurred during the first 3 years after diagnosis. However, our results were promising as only 3 relapse events have occurred 3/19 (15.8%), with no one developing locoregional recurrence, so metronomic capecitabine might be associated with decreased incidence of relapse in first 3 years in patients with TNBC. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The aim of this study is to investigate efficacy and toxicity of 1 year of capecitabine metronomic therapy preceded by standard adjuvant chemotherapy in triple-negative breast cancer (TNBC) patients.
    Journal of the Egyptian National Cancer Institute 11/2014; 26(4). DOI:10.1016/j.jnci.2014.10.002
  • Source
    • "As for the association between TNBC and axillary lymph node metastasis, some studies have shown that TNBC has a higher rate of axillary lymph node metastasis, while others have not found such association (Albergaria et al., 2011). Some studies have even found that TNBC has a lower rate of lymph node metastasis (Tischkowitz et al., 2007), while we have found that TNBC patients have a much higher rate of lymph node positivity. Therefore, further investigations are needed in this aspect. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Aims: To determine the clinical, pathological and prognostic features associated with triple-negative breast cancer (TNBC). Methods: Clinical and histologic data of 21,749 breast cancer patients who were treated at Tianjin Medical University Cancer Institute and Hospital between July 2002 and December 2011 were collected. Patients were divided into two groups: those with TNBC and those with other types of breast cancer. Patients and tumor characteristics were compared between the two groups using the Chi-square test. The prognostic results of 9,823 patients in the study population were also analyzed to determine long-term survival rates in the two groups of breast cancer patients. Results: Among the breast cancer patients treated in our hospital between 2003 and 2011, 10.4%-13.5% of them had triple-negative breast cancers. Data analyses revealed significant differences in disease onset age, family history of breast cancer, tumor size, tumor histologic grade, lymph note positivity and metastatic status between TNBC and non-TNBC patients. There were also significant differences in 5-year, 7-year and 9-year disease-free and 7-year and 9-year overall survival probability between the groups. Conclusions:TNBC are associated with younger disease onset age, larger tumor size, higher rate of axillary lymph node positivity, and higher tumor histologic grade. TNBC is also related to family history of breast cancer, increased metastatic risk and poor prognosis.
    Asian Pacific journal of cancer prevention: APJCP 06/2013; 14(6):3779-84. DOI:10.7314/APJCP.2013.14.6.3779 · 2.51 Impact Factor
Show more